Last updated on October 2016

TK216 in Patients With Relapsed or Refractory Ewing Sarcoma


Brief description of study

Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data to assess the potential of TK216 for further development.

Clinical Study Identifier: NCT02657005

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Noah Federman, MD

UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA United States
  Connect »

Paul A Meyers, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Joseph A Ludwig, MD

UT MD Anderson Cancer Center
Houston, TX United States
  Connect »